Clinical trials update from the European Society of Cardiology: CARMEN, EARTH, OPTIMAAL, ACE, TEN-HMS, MAGIC, SOLVD-X and PATH-CHF II

European Journal of Heart Failure

Volumn 4, Issue 5, 2002, Pages 661-666

  Coletta, A P ^a   Louis, A A ^a   Clark, A L ^a   Nikitin, N ^a   Cleland, J G F ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

ACE; CARMEN; EARTH; Heart failure; MAGIC; OPTIMAAL; PATH CHF II; SOLVD X; TEN HMS

Indexed keywords

AMINOTRANSFERASE; ANGIOTENSIN II ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CAPTOPRIL; CARVEDILOL; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; ENOXAPARIN; ENRASENTAN; HEPARIN DERIVATIVE; LOSARTAN; MAGNESIUM SULFATE; PHENPROCOUMON; PLACEBO; TEZOSENTAN;

AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CARDIOLOGY; CLINICAL TRIAL; DRUG FATALITY; DRUG TOLERABILITY; EMBOLISM; EUROPE; GERMANY; HEART FAILURE; HEART PACING; HEART VENTRICLE REMODELING; HOME CARE; HOME MONITORING; HUMAN; HYPOTENSION; MEDICAL SOCIETY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STROKE; TELECOMMUNICATION; VERTIGO;

CARDIOLOGY; CLINICAL TRIALS; EUROPE; HEART FAILURE, CONGESTIVE; HUMANS; SOCIETIES, MEDICAL; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0036802702     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(02)00176-9     Document Type: Review

References (17)

1. CARMEN Steering Committee and Investigators, Remme WJ. The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure EvaluatioN trial (CARMEN) - Rationale and design. Cardiovasc Drugs Ther 2001;15:69-77.
2. Greenberg B, Quinones MA, Koilpillai MA, et al. Effects of long term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography sub-study. Circulation 1995;91(10):2573-81.
3. Mylona P, Cleland JGF. Update of REACH-1 and MERIT-HF clinical trials in heart failure. Eur J Heart Fail 1999;1:197-200.
4. Coletta A, Thackray S, Nikitin N, Cleland JGF. Clinical trials update: Highlights of the scientific sessions of the American College of Cardiology 2002: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL. Eur J Heart Fail 2002;4:381-8.
5. Louis A, Cleland JGF, Crabbe S, et al. Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2 and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the scientific sessions of the American College of Cardiology 2001. Eur J Heart Fail 2001;3:381-7.
6. Cowbum PJ, Cleland JG. Endothelin antagonists for chronic heart failure: Do they have a role? Eur Heart J 2001;19:1772-84.
7. Thackray SD, Witte KK, Khand A, Dunn A, Clark AL, Cleland JG. Clinical trials update: Highlights of the scientific sessions of the American Heart Association year 2000: ValHeFT, COPERNICUS, MERIT, CIBIS-II, BEST, AMIOVERT, VMAC, BREATHE, HEAT, MIRACL, FLORIDA, VIVA and the first human cardiac skeletal muscle myoblast transfer for heart failure. Eur J Heart Fail 2001;31:117-24.
8. Coletta AP, Cleland JGF. Clinical trials update: Highlights of the scientific sessions of the XXIII congress of the European Society of Cardiology - WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur J Heart Fail 2001;3:747-50.
9. OPTIMAAL Study Group, Dickstein K, Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction. The OPTIMAAL trial design. Am J Cardiol 1999;83:477-81.
10. OPTIMAAL Trial Steering Committee and Investigators, Dickstein K, Kjekshus J. Comparison of baseline data, initial course and management; losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). Am J Cardiol 2001;87:766-71.
11. The OPTIMAAL Steering Committee for the OPTIMAAL Study Group, Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Lancet 2002;360:752-60.
12. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:995-1003.
13. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861-9.
14. Anticoagulation in Cardioversion using Enoxaparin Study Group, Stellbrink C, Hanrath P, Nixdorff U. Low molecular weight heparin for prevention of thromboembolic complications during cardioversion - Rationale and design of the ACE study (Anticoagulation in Cardioversion using Enoxaparin). Z Kardiol 2002;91:249-54.
15. The SOLVD Investigators. Effect on enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
16. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
17. PATH-CHF II Study Group, Stellbrink C, Auricchio A, Butter C, et al. Pacing therapies in congestive heart failure II study. Am J Cardiol 2000;86(Suppl):138k-143k.